PYPD vs AGIO vs ACRS

For growth investors, Agios Pharmaceuticals, Inc.

(AGIO) is the stronger pick with 48. 0% revenue growth year-over-year, versus -58. 2% for Aclaris Therapeutics, Inc. (ACRS). Analysts rate Agios Pharmaceuticals, Inc. (AGIO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Agios Pharmaceuticals, Inc.

(AGIO) delivered a total return of -50. 7%, compared to -98. 3% for PolyPid Ltd. (PYPD). Over 10 years, the gap is even starker: AGIO returned -41. 7% versus PYPD's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Aclaris Therapeutics, Inc.

(ACRS) is the lower-risk stock at 0. 22β versus Agios Pharmaceuticals, Inc. 's 1. 10β — meaning AGIO is approximately 403% more volatile than ACRS relative to the S&P 500. On balance sheet safety, Agios Pharmaceuticals, Inc. (AGIO) carries a lower debt/equity ratio of 5% versus 25% for PolyPid Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agios Pharmaceuticals, Inc.

(AGIO) is pulling ahead at 48. 0% versus -58. 2% for Aclaris Therapeutics, Inc. (ACRS). On earnings-per-share growth, the picture is similar: Aclaris Therapeutics, Inc. grew EPS 69. 0% year-over-year, compared to -161. 2% for Agios Pharmaceuticals, Inc.. Over a 3-year CAGR, AGIO leads at 56. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

PolyPid Ltd.

(PYPD) is the more profitable company, earning 0. 0% net margin versus -829. 6% for Aclaris Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PYPD leads at 0. 0% versus -975. 9% for ACRS. At the gross margin level — before operating expenses — AGIO leads at 78. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Aclaris Therapeutics, Inc.

(ACRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 22)). Both have compounded well over 10 years (ACRS: -76. 0%, PYPD: -99. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PYPD is a small-cap quality compounder stock; AGIO is a small-cap high-growth stock; ACRS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.